ALKERMES | ALKS - Ebitda

Prezzo Delle Azioni
33.31
Cambio Giornaliero
-0.60 -1.77%
Mensile
13.42%
Annuale
19.65%
Q2 Previsione
32.32




Ebitda Cambiamento Data
AbbVie USD 3.52B 828M 2025-09
Acadia Pharmaceuticals USD 35.76M 447K 2025-09
ALKERMES USD 100.31M 21.24M 2025-12
Amgen USD 5.14B 775M 2025-12
Biogen USD 573.2M 253.7M 2025-12
BioMarin Pharmaceutical USD -24.17M 18.91M 2025-12
Bristol-Myers Squibb USD 4.24B 967M 2025-09
Coherus Biosciences USD -43.33M 4.7M 2025-09
Eli Lilly USD 7.88B 378.1M 2025-09
Gilead Sciences USD 3.02B 1.01B 2025-12
Heron Therapeutics USD -3.88M 5.63M 2024-09
Ionis Pharmaceuticals USD -157.12M 307.36M 2025-09
J&J USD 7.19B 2.32B 2025-12
Malin Corporation EUR -1.1M 200K 2024-12
Merck USD 8.39B 1.97B 2025-09
Minerva Neurosciences USD -4.36M 1.71M 2024-09
Nektar Therapeutics USD -31.81M 70K 2023-09
Neurocrine Biosciences USD 218.4M 28.3M 2025-12
Otsuka Holdings JPY 99.77B 94.02B 2025-12
Pfizer USD 6.08B 351M 2025-09
Regeneron Pharmaceuticals USD 1.92B 261.9M 2025-09
Vertex Pharmaceuticals USD 1.44B 100.4M 2025-09